9 results about "Midazolam" patented technology

The present disclosure relates to a method of treatment or prophylaxis of a preterm infant by administering intravenously a therapeutic amount of a composition comprising IGF-1 and IBGBP-3 in combination with a therapy selected from the group comprising: caffeine, fentanyl, fluconazole, gentamicin, insulin, midazolam, morphine, low dose norepinephrine, vancomycin concentrations of 5 mg / ml or less, parenteral nutrition (or a composition for the same use) and combinations thereof.

Compositions for intranasal delivery of benzodiazepines, such as diazepam, midazolam, and lorazepam and methods for their use to treat and prevent seizures in pediatric subjects aged 2-5, inclusive. Compositions for rapid therapeutic onset with a decreased incidence and / or severity of adverse effects after administration and methods of improving patient compliance with a prescribed treatment regimen.

This invention relates to a midazolam nanocrystal suspension, which, by weight-volume percentage, comprises 5%–45% midazolam, 1%–10% Tween, and 0.1%–10% sodium deoxycholate (SDC). The midazolam nanocrystal suspension of this invention exhibits superior blood-brain barrier permeability and bioavailability, making it suitable for needle-free injection administration.

The present invention relates to a unit dose composition comprising midazolam or a pharmaceutically acceptable salt thereof, cyclodextrin, and at least one matrix material, and to the use of the unit dose composition in pharmaceuticals and therapies, particularly in the treatment of febrile seizures, epileptic seizures, e.g., status epilepticus, fear, e.g., preoperative anxiety relief to alleviate fear, and / or agitation, e.g., preoperative agitation.

The invention provides an automatic optical detection method and system for visible foreign matters in a midazolam buccal mucosa solution, and relates to the technical field of drug detection.The automatic optical detection method comprises the steps that the midazolam buccal mucosa solution is controlled to flow in a transparent flow cell, and suspended particles in the solution are dynamically observed and recognized by means of an optical imaging system; controlling a polarized light source of the optical imaging system to rotate relative to the transparent flow cell, and collecting optical response data of each suspended particle at a plurality of rotation angles; then, according to the data, determining the change information of the light intensity along with the relative rotation angle, synchronously extracting color distribution information, and generating key feature data representing the optical response characteristics of the particles; and finally, comparing the key characteristic data with preset standard characteristic data of the raw material medicines and the auxiliary materials, so that the suspended particles are judged as raw material medicine crystals, auxiliary material precipitates or visible foreign matters, and automatic and accurate classification of the suspended particles in the midazolam buccal mucosa solution is realized.

The application provides a method and system for automatically optically detecting visible foreign matters in midazolam buccal mucosa solution, and relates to the technical field of drug detection. The application controls the flow of midazolam buccal mucosa solution in a transparent flow cell, dynamically observes and identifies suspended particles in the solution by means of an optical imaging system. Then, the polarized light source of the optical imaging system is controlled to rotate relative to the transparent flow cell, and optical response data of each suspended particle at multiple rotation angles is collected. Next, the change information of light intensity with the relative rotation angle is determined according to the data, and the color distribution information is synchronously extracted to generate key feature data representing the optical response characteristics of the particles. Finally, the key feature data is compared with the preset standard feature data of the raw materials and excipients, so that the suspended particles are determined as raw material crystals, excipient precipitates or visible foreign matters, and the automatic and accurate classification of the suspended particles in the midazolam buccal mucosa solution is realized.

The invention discloses a closed-loop transcranial stimulation system and a closed-loop transcranial stimulation method. 0.3 mg of scopolamine and 3 mg of midazolam are intramuscularly injected before an operation; after a patient enters a room, sufentanil is subjected to intravenous injection induced by right subclavian vein and radial artery puncture general anesthesia, propofol is subjected to target-control infusion, the plasma target concentration is 3.0 mu g / mL, vecuronium bromide is 0.15 mg / kg, tracheal intubation is performed after 5 min, general anesthesia maintains target-control infusion of propofol, and after the patient enters the room, the target-control infusion of propofol is performed. A TMS stimulation coil electricity-magnetism-heat-stress model, a single-phase and double-phase pulse discharge circuit model and a neuron dynamic response model under the action of a TMS are established, and the influence of TMS system parameters on space-time distribution characteristics of an intracranial induced electric field and neuron membrane potential can be accurately expressed. Behavior perception and system auditory stimulation are combined to be applied to nursing intervention of severe craniocerebral injury coma patients, self-repairing and consciousness awakening of the brain functions of the patients can be effectively promoted, and meanwhile recovery of limb functions and daily life ability of the patients is facilitated.

The application discloses a kind of pharmaceutical composition and its purposes in preparation for inhibiting the autonomous intake preference of ethanol. The pharmaceutical composition includes lorcaserin and midazolam. The pharmaceutical composition for inhibiting the autonomous intake preference of ethanol provided by the application can effectively reduce the desire of body to alcohol, is used to treat alcohol dependence, and has significant long-acting characteristics. When the pharmaceutical composition is administered to mice, the absolute amount of active ethanol intake of mice and the relative proportion of ethanol intake compared with the amount of drinking water can be significantly reduced, and the inhibitory effect can last at least 6 days, which is expected to update the treatment plan for alcohol addiction in clinic.

This invention discloses a method for preparing midazolam impurity A and impurity B standards. It improves the preparation method of the key intermediate 4-hydroxymidazolam, using 4-hydroxymidazolam as a raw material and further preparing impurities A and B through different pathways. In the preparation of 4-hydroxymidazolam, only one post-processing step is performed, avoiding losses caused by multiple post-processing steps, improving yield, and resulting in high product purity. This, in turn, improves the purity of the target products, impurities A and B, providing strong support for the quality of midazolam pharmaceutical products.